Ring, Alexander
Campo, Daniel
Porras, Tania B.
Kaur, Pushpinder
Forte, Victoria A.
Tripathy, Debu
Lu, Janice
Kang, Irene
Press, Michael F.
Jeong, Young Ju
Snow, Anson
Zhu, Yue
Zada, Gabriel
Wagle, Naveed
Lang, Julie E.
Funding for this research was provided by:
ANGLE plc. (Personal grant to J.E.L.)
National Cancer Institute (P30CA014089)
Article History
Received: 3 September 2021
Accepted: 11 October 2021
First Online: 9 January 2022
Change Date: 8 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1245/s10434-022-11589-y
Disclosures
: The authors declare no competing interests for the presented study. Although ANGLE plc provided research funds to the author’s institution, the authors have no relevant financial disclosures. The study sponsor did not influence data acquisition, analysis or the decision to publish.Debasish Tripathy: Research support (paid to institution): Novartis, Pfizer, Polyphor Consulting fees (paid to self): AstraZeneca, GlaxoSmithKline, Gilead, Exact Sciences, OncoPep, Novartis, Pfizer. Irene Kang: Puma Biotechnology – speaker’s bureau, consulting fees Bristol Myers Squibb — consulting fees. Michael Press: Consulting or advisory role: AstraZenecca, Biocartis, Cepheid, Inc.; Eli Lilly & Company, Merck & Co., Puma Biotechnology; Expert testimony: Amgen, Inc.; Private equity: TORL Biotherapeutics, LLC.